November 30, 2019 Eric B. Mosbrooker Re: RETENTION AGREEMENT Dear Eric:Retention Agreement • December 16th, 2019 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your continued engagement during a retention period (the “Retention Period”) following the consummation of the transaction contemplated by the Merger Agreement (the “Merger”) is essential to ensuring that the enterprise is a success. Accordingly, the Company wishes to amend the Executive Employment Agreement between you and the Company, dated as of January 3, 2019 (as amended by this letter, your “Employment Agreement”) as provided in this letter (this “Letter”). This Letter shall become effective as of the consummation of the Merger (the “Closing”) and is conditioned on the occurrence of the Closing. Capitalized terms used but not defined in this Letter have the meanings set forth in the Employment Agreement.
